About Mitogen-activated protein kinase 14
Mitogen-activated protein kinase 14 (MAPK14) is a protein
from Homo sapiens identified by UniProt accession
Q16539, 360 residues long.
MolForge cross-references it against 0 known binders and
624 disease associations.
Target properties
| Protein name | Mitogen-activated protein kinase 14 |
| UniProt accession | Q16539 |
| Gene | MAPK14 |
| Organism | Homo sapiens |
| Length | 360 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (624)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- neuroinflammatory disorder · score 0.46
- Alzheimer disease · score 0.33
- Parkinson disease · score 0.31
- multiple sclerosis · score 0.31
- lysosomal storage disease · score 0.30
- Facioscapulohumeral dystrophy · score 0.29
- acute coronary syndrome · score 0.29
- breast adenocarcinoma · score 0.28
- endometrial cancer · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16539-F1 | alphafold | PREDICTED | 89.77 | — |
Amino-acid sequence (360 residues)
MSQERPTFYR QELNKTIWEV PERYQNLSPV GSGAYGSVCA AFDTKTGLRV AVKKLSRPFQ SIIHAKRTYR ELRLLKHMKH ENVIGLLDVF TPARSLEEFN DVYLVTHLMG ADLNNIVKCQ KLTDDHVQFL IYQILRGLKY IHSADIIHRD LKPSNLAVNE DCELKILDFG LARHTDDEMT GYVATRWYRA PEIMLNWMHY NQTVDIWSVG CIMAELLTGR TLFPGTDHID QLKLILRLVG TPGAELLKKI SSESARNYIQ SLTQMPKMNF ANVFIGANPL AVDLLEKMLV LDSDKRITAA QALAHAYFAQ YHDPDDEPVA DPYDQSFESR DLLIDEWKSL TYDEVISFVP PPLDQEEMES
Explore Mitogen-activated protein kinase 14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets